Founded in 2011 as a Moffitt Cancer Research Center spinoff, Modulation Therapeutics is a Morgantown clinical-stage biotechnology company developing therapies for aggressive solid-tumor cancers and liver disease. Its research team combines targeted alpha radiotherapy with peptide and small-molecule drug development, including a therapy for metastatic melanoma that has received FDA Orphan Drug and Fast Track designations. The privately held company moved its primary operations to West Virginia in 2016 and works with West Virginia University researchers to advance its pipeline toward clinical use.
Zetagen TherapeuticsFounded in 2015, Zetagen Therapeutics is a private, clinical-stage biopharmaceutical company built around a patient-centered approach to cancer research. From its Colleen Connor Cancer Research Lab, the company develops local treatments for people with metastatic cancer affecting bone, including the investigational therapy ZetaMet, which is designed to address tumors while supporting bone repair.SYRACUSE, NY
Duo OncologyFounded by nanoparticle and drug-delivery researchers, Pittsburgh-based Duo Oncology is a clinical-stage biotechnology company developing tumor-activated medicines for cancer treatment. Its lead program, DUO-207, is designed to simplify chemotherapy by concentrating drug activity in tumors while reducing exposure in healthy tissue.PITTSBURGH, PA
MetasTx, LLCPittsburgh-based MetasTx, LLC is developing a precision-oncology platform that pairs a diagnostic for identifying prostate cancer patients at high risk of metastasis with next-generation KIT inhibitors intended to block cancer spread and treatment resistance. Its NCI-supported diagnostic study with Allegheny Health Network and licensed inhibitor compounds from the Crich UGARF laboratories connect clinical research with a targeted therapeutic program. The company’s leadership brings experience from institutions and oncology organizations including Merck and AstraZeneca.PITTSBURGH, PA
Molecular Targeting Technologies, IncPrivately held and clinical-stage, Molecular Targeting Technologies, Inc. is known for advancing radiopharmaceutical research aimed at rare cancers. Its EvaThera platform, licensed worldwide from the National Institutes of Health, supports targeted diagnosis and treatment for patients whose tumors express specific molecular markers.WEST CHESTER, PA